cis-4-Benzyl-2,6-dimethylmorpholin | 61883-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cis-4-Benzyl-2,6-dimethylmorpholin
• 英文别名: 4-benzyl-2,6-dimethyl-morpholine；4-Benzyl-cis-2,6-dimethylmorpholine；(2R,6S)-4-benzyl-2,6-dimethylmorpholine
• CAS: 61883-58-7
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: LLKJAIKKDGIIJW-TXEJJXNPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-4-Benzyl-2,6-dimethylmorpholin 在 sodium periodate 、 四氧化钌 作用下， 以 四氯化碳 、 水 为溶剂， 反应 7.0h， 生成 4-benzyl-2,6-dimethyl-morpholin-3-one 、 4-benzoyl-cis-2,6-dimethylmorpholine
  参考文献：
  名称：

  Oxidation of Morpholine Derivatives with Ruthenium-(VIII) Oxide

  摘要：

  DOI：

  10.1055/s-1976-24131
• 作为产物：
  描述：

  苯甲酸 、 2,6-二甲基吗啉 在 trimethylamine borane 作用下， 以 xylene 为溶剂， 反应 7.0h， 以12%的产率得到(2S,6S)-4-benzyl-2,6-dimethylmorpholine
  参考文献：
  名称：

  Trimethylamine-Borane as Useful Reagent in theN-Acylation orN-Alkylation of Amines by Carboxylic Acids

  摘要：

  DOI：

  10.1055/s-1983-30605

文献信息

• Tricyclic tetrahydroquinoline antibacterial agents
  申请人：——

  公开号：US20040162279A1

  公开（公告）日：2004-08-19

  The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.

  该发明涉及式I的四氢喹啉及相关化合物，以及其制备的药物组合物，对人类和兽医病原体具有有用的抗菌活性。
• TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS
  申请人：Barbachyn Michael Robert

  公开号：US20100022524A1

  公开（公告）日：2010-01-28

  The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.

  该发明涉及公式I的四氢喹啉及相关化合物，以及其制备的药物组合物，对于广泛的人类和兽医病原体具有有用的抗菌活性。
• Tricyclic Tetrahydroquinoline Antibacterial Agents
  申请人：Barbachyn Michael Robert

  公开号：US20110092494A1

  公开（公告）日：2011-04-21

  The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.

  该发明涉及公式I的四氢喹啉及相关化合物，以及其制备的药物组合物，对人类和兽医病原体具有有用的抗菌活性。
• QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140309227A1

  公开（公告）日：2014-10-16

  The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, R Q , -L-, R 1 , n, R 2 , and R 3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了公式（I）中环A、RQ、-L-、R1、n、R2和R3所定义的喹啉羧酰胺和喹啉羰基化合物。本发明的化合物可用作非竞争性mGluR2拮抗剂或mGluR2负向变构调节剂（NAMs），并且用于治疗患有mGluR2-NAM受体参与的疾病或障碍的患者（优选为人类），例如阿尔茨海默病、认知障碍、精神分裂症和其他情绪障碍、疼痛障碍和睡眠障碍，通过向患者投予本发明化合物或其药学上可接受的盐的治疗有效剂量。本发明还涉及包含本发明化合物或其药学上可接受的盐（可选与一种或多种其他活性成分组合）和药学上可接受的载体的制药组合物，以及本发明化合物和制药组合物在治疗此类疾病中的应用。
• Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use
  申请人：Merck Sharp & Dohme Corp

  公开号：US20160158217A1

  公开（公告）日：2016-06-09

  The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, R Q , -L-, R 1 , n, R 2 , and R 3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了式（I）的喹啉羧酰胺和喹啉羰基化合物，其中环A、RQ、-L-、R1、n、R2和R3的定义如本文所述。本发明的化合物可用作非竞争性mGluR2拮抗剂，或mGluR2负向变构调节剂（NAMs），并用于治疗患有mGluR2-NAM受体参与的疾病或障碍的患者（优选为人类），包括潜在的阿尔茨海默病，认知障碍，精神分裂症和其他情绪障碍，疼痛障碍和睡眠障碍，通过向患者施用本发明化合物或其药学上可接受的盐的治疗有效量。本发明还涉及包含本发明化合物或其药学上可接受的盐（可选与一种或多种其他活性成分组合）和药学上可接受的载体的制药组合物，以及在治疗这些疾病中使用本发明的化合物和制药组合物。